Your browser is no longer supported. Please, upgrade your browser.
Settings
TNXP Tonix Pharmaceuticals Holding Corp. daily Stock Chart
TNXP [NASD]
Tonix Pharmaceuticals Holding Corp.
Index- P/E- EPS (ttm)-28.85 Insider Own0.30% Shs Outstand1.53M Perf Week-29.95%
Market Cap4.33M Forward P/E- EPS next Y-10.63 Insider Trans- Shs Float1.39M Perf Month-56.46%
Income-24.00M PEG- EPS next Q-3.68 Inst Own12.20% Short Float98.69% Perf Quarter-65.38%
Sales- P/S- EPS this Y79.40% Inst Trans-23.08% Short Ratio2.19 Perf Half Y-93.34%
Book/sh14.30 P/B0.20 EPS next Y57.30% ROA-116.80% Target Price18.13 Perf Year-92.59%
Cash/sh- P/C- EPS next 5Y- ROE-131.90% 52W Range2.64 - 51.10 Perf YTD-91.80%
Dividend- P/FCF- EPS past 5Y43.70% ROI- 52W High-94.46% Beta1.20
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low7.20% ATR1.26
Employees14 Current Ratio6.80 Sales Q/Q- Oper. Margin- RSI (14)36.64 Volatility41.78% 23.86%
OptionableYes Debt/Eq0.00 EPS Q/Q25.80% Profit Margin- Rel Volume0.59 Prev Close2.72
ShortableNo LT Debt/Eq0.00 EarningsNov 20 AMC Payout- Avg Volume626.93K Price2.83
Recom2.60 SMA20-39.32% SMA50-50.04% SMA200-87.32% Volume371,740 Change4.04%
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
Dec-11-18 04:00PM  Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering GlobeNewswire
Dec-07-18 01:37PM  Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today InvestorPlace -6.67%
10:35AM  Tonix Pharmaceuticals Prices $15,000,000 Public Offering GlobeNewswire
Dec-03-18 07:00AM  Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target ACCESSWIRE -22.16%
Nov-29-18 07:00AM  Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes GlobeNewswire +83.42%
Nov-27-18 07:00AM  Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split GlobeNewswire -8.49%
Nov-21-18 07:35AM  Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-19-18 09:45AM  TNXP: Ready to Initiate Phase 3 Trial of TNX-102 SL in PTSD in 1Q19 Zacks Small Cap Research
Nov-09-18 07:53AM  Tonix: 3Q Earnings Snapshot Associated Press -10.29%
07:30AM  Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Nov-07-18 07:00AM  Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya® GlobeNewswire
Nov-06-18 07:00AM  Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 HONOR Study in Poster Presentation at CNS Summit 2018 GlobeNewswire
Nov-01-18 08:00AM  Todays Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals ACCESSWIRE -5.56%
07:00AM  Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference GlobeNewswire
Oct-31-18 10:05AM  Healthcare Market Growth Could Fuel These Stocks ACCESSWIRE +12.50%
07:00AM  Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting GlobeNewswire
Oct-29-18 07:00AM  Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018 GlobeNewswire
Oct-23-18 07:00AM  Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference GlobeNewswire
Oct-04-18 08:00AM  Todays Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies ACCESSWIRE
Sep-26-18 01:30PM  Tonix Pharmaceuticals to Present at the MicroCap Conference GlobeNewswire
Sep-20-18 07:00AM  Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference GlobeNewswire
Sep-07-18 07:00AM  Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D. GlobeNewswire
Aug-30-18 07:00AM  Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences GlobeNewswire
Aug-27-18 03:45PM  TNXP: Retrospective Analyses from HONOR and AtEase Trials Presented Zacks Small Cap Research
Aug-22-18 04:01PM  Tonix Pharmaceuticals Announces Director Stepping Down GlobeNewswire -8.46%
Aug-21-18 09:20AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium GlobeNewswire
Aug-15-18 11:46AM  Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium GlobeNewswire +13.73%
Aug-13-18 07:07AM  Tonix: 2Q Earnings Snapshot Associated Press
07:00AM  Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Aug-09-18 12:00PM  TNXP: HONOR Trial Stopped Early Following Interim Analysis... Zacks Small Cap Research
Jul-27-18 08:55AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga -65.78%
08:00AM  Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD GlobeNewswire
Jul-17-18 08:10AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Tonix Pharmaceuticals ACCESSWIRE
Jul-16-18 01:51PM  Tonix Shares Surge On Fast Struck Status For Alzheimer's-Related Agitation Candidate Benzinga +5.82%
09:26AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimers Disease GlobeNewswire
Jun-20-18 09:02AM  Bullish Insiders Bought More Of These Stocks In June Simply Wall St.
May-31-18 04:30PM  Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology GlobeNewswire +5.86%
May-30-18 08:00AM  Tonix Pharmaceuticals to Present at the 2018 BIO International Convention GlobeNewswire
May-24-18 07:00AM  Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL GlobeNewswire
May-23-18 04:05PM  Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology GlobeNewswire
May-14-18 07:08AM  Tonix: 1Q Earnings Snapshot Associated Press
07:00AM  Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update GlobeNewswire
May-07-18 07:00AM  Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention GlobeNewswire
May-01-18 08:24AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimers Disease GlobeNewswire
Apr-05-18 07:10AM  Blog Exposure - Tonix Pharma Announces 50% Enrolment in Tonmya® Study for PTSD ACCESSWIRE
Apr-04-18 07:00AM  Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York GlobeNewswire
Apr-03-18 07:00AM  Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD GlobeNewswire
Mar-26-18 04:05PM  Eyenovia Appoints Three Industry Veterans to Board of Directors GlobeNewswire
Mar-21-18 04:05PM  Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL GlobeNewswire
Mar-19-18 04:45PM  TNXP: Phase 3 Trial in PTSD Nearing 50% Enrollment; Interim Analysis in 3Q18 Zacks Small Cap Research -5.37%
Mar-13-18 07:00AM  Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium GlobeNewswire
Mar-12-18 07:23AM  Tonix reports 4Q loss Associated Press
07:00AM  Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update GlobeNewswire
Mar-06-18 07:00AM  Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-15-18 07:00AM  Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors GlobeNewswire
Feb-07-18 04:30PM  Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City GlobeNewswire
Jan-24-18 04:30PM  Tonix Pharmaceuticals to Present at Noble Capital Markets Fourteenth Annual Investor Conference in Fort Lauderdale GlobeNewswire -7.51%
Jan-23-18 09:30AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +5.45%
07:20AM  Blog Exposure - Tonix Declares Publication of Research about Potential Smallpox-Preventing Vaccine Candidate TNX-801 ACCESSWIRE
07:00AM  Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) GlobeNewswire
Jan-19-18 02:00PM  Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture) GlobeNewswire
Jan-09-18 07:00AM  Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer GlobeNewswire
Jan-08-18 02:00PM  TNXP: Ready to File IND to Study TNX 102-SL in Agitation in Alzheimers Disease Zacks Small Cap Research
Jan-05-18 07:30PM  What Are Analysts Saying About Tonix Pharmaceuticals Holding Corps (NASDAQ:TNXP) Future? Simply Wall St. -5.03%
Jan-03-18 07:00AM  Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco GlobeNewswire
Dec-13-17 01:00PM  TNXP: The Origin of the Smallpox Vaccine and the Implications for TNX-801 Zacks Small Cap Research -5.26%
Dec-12-17 07:00AM  Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimers Disease GlobeNewswire
Nov-30-17 07:00AM  Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference GlobeNewswire
Nov-07-17 07:31AM  Tonix reports 3Q loss Associated Press
07:00AM  Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update GlobeNewswire
Nov-01-17 07:00AM  Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference GlobeNewswire
Oct-17-17 07:00AM  Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD GlobeNewswire -7.17%
Oct-12-17 07:00AM  Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference GlobeNewswire
Oct-05-17 11:16AM  Tonix Pharmaceuticals Holding Corps (TNXP): From Cash To Ash? Simply Wall St.
Sep-29-17 07:00AM  Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C. GlobeNewswire
Sep-14-17 04:05PM  Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) GlobeNewswire
07:00AM  Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors GlobeNewswire
Sep-11-17 07:20AM  Corporate News Blog - Eli Lilly's Galcanezumab Treatment Shows Positive Safety Results in the 12-Month Phase-3 Study ACCESSWIRE
Sep-06-17 07:00AM  Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire +6.46%
Aug-29-17 04:30PM  Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium GlobeNewswire
Aug-21-17 07:00AM  Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium GlobeNewswire
Aug-17-17 12:15PM  TNXP: Patient Enrollment Continues for Phase 3 Study of Tonmya® in PTSD; Interim Analysis Expected in 1H18 Zacks Small Cap Research
Aug-14-17 10:24PM  Tonix reports 2Q loss Associated Press
07:00AM  Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update GlobeNewswire
Jul-06-17 07:00AM  Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD GlobeNewswire
Jun-16-17 07:00AM  Tonix Pharmaceuticals to Present at the 2017 BIO International Convention GlobeNewswire
Jun-15-17 07:00AM  Tonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets Summit Sponsored by U.S. Department of Defense GlobeNewswire
Jun-13-17 08:15AM  Corporate News Blog - Lilly Announces Galcanezumab Results Presented at AHS; Reported Reduced Number of Migraine Headache Days for Patients with Acute Migraine Accesswire
Jun-12-17 07:00AM  Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference GlobeNewswire
May-30-17 04:30PM  Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study GlobeNewswire
May-24-17 07:00AM  Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting GlobeNewswire
May-22-17 04:05PM  Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Calithera Biosciences Accesswire
May-18-17 12:30PM  TNXP: Interim Analysis for HONOR Study Expected in 1H18 Zacks Small Cap Research
May-15-17 07:10AM  Tonix reports 1Q loss Associated Press
07:00AM  Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update GlobeNewswire
May-11-17 07:00AM  Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention GlobeNewswire
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEDERMAN SETHChief Executive OfficerJun 29Buy4.645002,32017,666Jul 02 04:30 PM
LEDERMAN SETHChief Executive OfficerJun 28Buy4.585002,29017,166Jun 29 04:30 PM
LEDERMAN SETHChief Executive OfficerJun 27Buy4.555002,27516,666Jun 28 04:30 PM
MARIO ERNESTDirectorJun 25Buy4.4816,50073,92050,000Jun 27 04:30 PM
SULLIVAN GREGORY MChief Medical OfficerJun 14Buy3.9710,00039,65020,482Jun 15 07:05 AM
SAENGER BRADLEYChief Financial OfficerJun 14Buy4.103001,2303,079Jun 14 04:05 PM
MORRIS JESSICA EDGARChief Operating OfficerJun 14Buy4.193001,2571,638Jun 14 04:05 PM
LEDERMAN SETHChief Executive OfficerJun 12Buy4.372,0008,74020,463Jun 14 04:06 PM
LEDERMAN SETHChief Executive OfficerJun 12Buy4.371,0004,37016,166Jun 14 04:06 PM
Rhodes John BDirectorJun 01Buy3.337,50024,97523,470Jun 06 04:05 PM
LEDERMAN SETHChief Executive OfficerMay 25Buy3.174,00012,68026,700May 30 04:05 PM
LEDERMAN SETHChief Executive OfficerDec 26Buy3.615,30019,13322,700Dec 27 02:04 PM
MARIO ERNESTDirectorDec 21Sale3.465,00017,30023,500Dec 22 04:58 PM
MARIO ERNESTDirectorDec 20Sale3.448,96530,84028,500Dec 22 04:58 PM
MARIO ERNESTDirectorDec 19Sale3.516,03521,18337,465Dec 22 04:58 PM
MARIO ERNESTDirectorDec 18Sale3.5710,00035,70043,500Dec 22 04:58 PM
MARIO ERNESTDirectorDec 15Sale3.555,00017,75053,500Dec 22 04:58 PM
MARIO ERNESTDirectorDec 14Sale3.581,9677,04255,467Dec 22 04:58 PM